Viome Nutritional Programs to Improve Clinical Outcomes for Mental Health Conditions

Sponsor
Viome (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05563857
Collaborator
(none)
150
1
3
2.4
61.7

Study Details

Study Description

Brief Summary

US residents who have mental health issues sign the informed consent form and are screened and enrolled for this study. Participants who are enrolled complete a survey upon enrollment and are randomized into one of three arms. This study is direct to participant and will NOT utilize clinical sites.

Condition or Disease Intervention/Treatment Phase
  • Combination Product: VIOME Precision Nutrition Program
  • Dietary Supplement: VIOME-designed condition-based supplements
N/A

Detailed Description

Participants who meet the eligibility criteria are randomized into any of the three arms including: the control arm, VIOME's condition-based supplements (VCS) arm or the VIOME Precision Nutrition Program (VPNP) arm.

Placebo, Viome-designed condition-based supplements and Viome's Precision Nutrition Program include supplements, may include dietary recommendations towards improving the symptoms associated with mental wellness. The trial will last approximately 4 months for each participant.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized, blinded, cohort study divided into three arms: 1) control group (placebo), 2) condition-based supplement, 3) precision-supplementRandomized, blinded, cohort study divided into three arms: 1) control group (placebo), 2) condition-based supplement, 3) precision-supplement
Masking:
Single (Participant)
Masking Description:
Once enrolled, participants are randomized into one of the three arms. The coded supplements with blinded labels are shipped to the participants. The participants are not aware of which group they are randomized into.
Primary Purpose:
Supportive Care
Official Title:
Testing the Efficacy of Viome-designed Condition-based Supplements and Viome Precision Supplements to Improve Clinical Outcomes for Mental Health Conditions
Actual Study Start Date :
Oct 19, 2022
Anticipated Primary Completion Date :
Jan 1, 2023
Anticipated Study Completion Date :
Jan 1, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Placebo

Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Placebo capsules will contain inert and inactive materials. Participants may need to use a mobile app in order to participate in the trial.

Active Comparator: Viome's Precision Nutrition Program (VPNP)

Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.

Combination Product: VIOME Precision Nutrition Program
Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
Other Names:
  • VPNP
  • Active Comparator: Viome's condition-based supplements

    Participants who have mental health issues are randomized into this arm. They may be provided with any combination of nutritional recommendations and supplements. Participants may need to use a mobile app in order to participate in the trial.

    Dietary Supplement: VIOME-designed condition-based supplements
    Pre-formulated supplements based on overall health conditions.
    Other Names:
  • VCS
  • Outcome Measures

    Primary Outcome Measures

    1. Reduced PHQ-9 Score [~4 months]

      Reduced PHQ-9 score for both VCS and VPNP groups compared to baseline scores.

    2. Reduced GAD-7 Score [~4 months]

      Reduced GAD-7 score for both VCS and VPNP groups compared to baseline scores.

    3. Reduced Perceived Stress Scale Score [~4 months]

      Reduced Perceived Stress Scale score for both VCS and VPNP groups compared to baseline scores.

    4. Increased Quality of Life Score [~4 months]

      Increased quality of life score for both VCS and VPNP groups compared to baseline scores.

    5. Correlation between microbial changes and clinical outcomes [~4 months]

      Correlation between microbial changes on VCS or VPNP with clinical outcomes.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    25 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Resident of the United States

    • Females and males ages 25-75 (inclusive)

    • Able to speak and read English

    • No unexplained weight loss, fevers, anemia, or blood in stool

    • Willing and able to follow the trial instructions, as described in the recruitment letter

    • Signed and dated informed consent prior to any trial-specific procedures.

    • PHQ9 score of 5-24 (inclusive)

    Exclusion criteria

    • Answer of 1, 2, or 3 on question 9 of PHQ9

    • Unwilling to change their current diet

    • Prior use of Viome products or services

    • Antibiotic use in the previous 3 months

    • Pregnancy (current or planned in the next 4 months)

    • < 90 days postpartum

    • Breast feeding

    • Active infection

    • Unable or unwilling to use Viome's App on an iPhone or Android smartphone

    • Significant diet or lifestyle change in the previous 3 months or next 4 months, unless it is a part of the trial

    • Prebiotic or probiotic supplement use in the previous 30 days

    • Regular use (> 3 days a week) of any products specifically marketed for gut health, such as DanActive, Activia, Yakult, multi grain/prebiotic cereals/bars, etc.

    • Regular use (> 3 days a week) of fermented foods, such as Kefir, Miso, Natto, Tempeh, Kimchi, Sourdough, Sauerkraut, Kombucha, etc.

    • IBD diagnosis -Major psychiatric/DSM-5 disease diagnosis (e.g. Schizophrenia, Bipolar disorder, Post- traumatic Stress Disorder, Obsessive Compulsive disorder)

    • Use of investigational drugs, products or devices within 1 month prior to and 4 months after the start of the trial

    • Cancer therapy within the previous 1 year

    • Major surgery in the last 6 months or planned in the next 4 months

    • Chronic pain syndrome other than IBS in past year

    • Start of a new prescription medication within the past 3 months or the next 4 months

    • Allergies to any supplement ingredients listed in the screening survey

    • Currently on a specific diet: FODMAP, KETO, PALEO

    • Gastrointestinal disease including:

    • GI surgery except:

    • Appendectomy and benign polypectomy

    • Esophagitis

    • Celiac disease

    • GI malignancy or obstruction

    • Peptic Ulcer Disease

    • Duodenal or gastric ulcer disease

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Viome Life Sciences Bothell Washington United States 98011

    Sponsors and Collaborators

    • Viome

    Investigators

    • Principal Investigator: Momchilo Vuyisich, Viome

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Viome
    ClinicalTrials.gov Identifier:
    NCT05563857
    Other Study ID Numbers:
    • V211.3
    First Posted:
    Oct 3, 2022
    Last Update Posted:
    Dec 27, 2022
    Last Verified:
    Dec 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Viome
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 27, 2022